Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.

Nirav R Shah; Jürgen B Bulitta; Martina Kinzig; Cornelia B Landersdorfer; Yuanyuan Jiao; Dhruvitkumar S Sutaria; Xun Tao; Rainer Höhl; Ulrike Holzgrabe; Frieder Kees; Ulrich Stephan; Fritz Sörgel

doi:10.3390/pharmaceutics11060286

Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.

Nirav R Shah, Jürgen B Bulitta, Martina Kinzig, Cornelia B Landersdorfer, Yuanyuan Jiao, Dhruvitkumar S Sutaria, Xun Tao, Rainer Höhl (Co-author), Ulrike Holzgrabe, Frieder Kees, Ulrich Stephan, Fritz Sörgel

Institute of Clinical Microbiology, Infectious Diseases and Infection Control

Research output: Contribution to journal › Original Article › peer-review

11 Citations (Web of Science)

Original language	English
Journal	PHARMACEUTICS
Volume	11
Issue number	6
DOIs	https://doi.org/10.3390/pharmaceutics11060286
Publication status	Published - 2019

Keywords

GLOMERULAR-FILTRATION-RATE
RENAL CLEARANCE
PHARMACODYNAMIC BREAKPOINTS
NONLINEAR PHARMACOKINETICS
ANTIBIOTIC-PROPHYLAXIS
CEFOTIAM
DISPOSITION
PLASMA
PIPERACILLIN
SERUM

Access to Document

10.3390/pharmaceutics11060286

Cite this

Shah, N. R., Bulitta, J. B., Kinzig, M., Landersdorfer, C. B., Jiao, Y., Sutaria, D. S., Tao, X., Höhl, R., Holzgrabe, U., Kees, F., Stephan, U., & Sörgel, F. (2019). Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. PHARMACEUTICS, 11(6). https://doi.org/10.3390/pharmaceutics11060286

@article{0540af3103f24a55b627bfa21423f7ba,

title = "Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.",

keywords = "GLOMERULAR-FILTRATION-RATE, RENAL CLEARANCE, PHARMACODYNAMIC BREAKPOINTS, NONLINEAR PHARMACOKINETICS, ANTIBIOTIC-PROPHYLAXIS, CEFOTIAM, DISPOSITION, PLASMA, PIPERACILLIN, SERUM",

author = "Shah, {Nirav R} and Bulitta, {J{\"u}rgen B} and Martina Kinzig and Landersdorfer, {Cornelia B} and Yuanyuan Jiao and Sutaria, {Dhruvitkumar S} and Xun Tao and Rainer H{\"o}hl and Ulrike Holzgrabe and Frieder Kees and Ulrich Stephan and Fritz S{\"o}rgel",

note = "H{\"o}hl, R: Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Klinikum N{\"u}rnberg, Paracelsus Medical University, N{\"u}rnberg 90419, Germany",

year = "2019",

doi = "10.3390/pharmaceutics11060286",

language = "English",

volume = "11",

journal = "PHARMACEUTICS",

issn = "1999-4923",

publisher = "MDPI",

number = "6",

}

Shah, NR, Bulitta, JB, Kinzig, M, Landersdorfer, CB, Jiao, Y, Sutaria, DS, Tao, X, Höhl, R, Holzgrabe, U, Kees, F, Stephan, U & Sörgel, F 2019, 'Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.', PHARMACEUTICS, vol. 11, no. 6. https://doi.org/10.3390/pharmaceutics11060286

TY - JOUR

T1 - Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.

AU - Shah, Nirav R

AU - Bulitta, Jürgen B

AU - Kinzig, Martina

AU - Landersdorfer, Cornelia B

AU - Jiao, Yuanyuan

AU - Sutaria, Dhruvitkumar S

AU - Tao, Xun

AU - Höhl, Rainer

AU - Holzgrabe, Ulrike

AU - Kees, Frieder

AU - Stephan, Ulrich

AU - Sörgel, Fritz

N1 - Höhl, R: Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg 90419, Germany

PY - 2019

Y1 - 2019

KW - GLOMERULAR-FILTRATION-RATE

KW - RENAL CLEARANCE

KW - PHARMACODYNAMIC BREAKPOINTS

KW - NONLINEAR PHARMACOKINETICS

KW - ANTIBIOTIC-PROPHYLAXIS

KW - CEFOTIAM

KW - DISPOSITION

KW - PLASMA

KW - PIPERACILLIN

KW - SERUM

U2 - 10.3390/pharmaceutics11060286

DO - 10.3390/pharmaceutics11060286

M3 - Original Article

C2 - 31216743

SN - 1999-4923

VL - 11

JO - PHARMACEUTICS

JF - PHARMACEUTICS

IS - 6

ER -